Affordable Access

deepdyve-link
Publisher Website

Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.

Authors
  • Shakir, Nabeel A1
  • George, Arvin K1
  • Siddiqui, M Minhaj1
  • Rothwax, Jason T1
  • Rais-Bahrami, Soroush1
  • Stamatakis, Lambros1
  • Su, Daniel1
  • Okoro, Chinonyerem1
  • Raskolnikov, Dima1
  • Walton-Diaz, Annerleim1
  • Simon, Richard2
  • Turkbey, Baris3
  • Choyke, Peter L3
  • Merino, Maria J4
  • Wood, Bradford J5
  • Pinto, Peter A6
  • 1 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • 2 Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • 3 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • 4 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • 5 Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • 6 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Clinical Center, National Institutes of Health, Bethesda, Maryland. Electronic address: [email protected]
Type
Published Article
Journal
The Journal of urology
Publication Date
December 2014
Volume
192
Issue
6
Pages
1642–1648
Identifiers
DOI: 10.1016/j.juro.2014.08.002
PMID: 25117476
Source
Medline
Keywords
License
Unknown

Abstract

Prostate cancer upgrading with targeted biopsy increases with an increasing prostate specific antigen cutoff. Above a prostate specific antigen threshold of 5.2 ng/ml most upgrading to clinically significant disease was achieved by targeted biopsy. In our population this corresponded to potentially sparing biopsy in 36% of patients who underwent multiparametric magnetic resonance imaging. Below this value 12-core biopsy detected more clinically insignificant cancer. Thus, the diagnostic usefulness of targeted biopsy is optimized in patients with prostate specific antigen 5.2 ng/ml or greater.

Report this publication

Statistics

Seen <100 times